CRISPR Therapeutics AG (CRSP) Catches Our Eye After Big Move

Director Cagnoni Pablo J sold 7,500 shares in CRISPR Therapeutics AG (NASDAQ:CRSP) in transaction occurred on 2018/07/05. After making this transaction, the Director owns a direct stake of 465,000 shares. On 2018/06/05 Emster Kurt Von, Director at CRSP, dumped 920 shares at an average price of $12.51 per share. The selling total is valued at $14,105,034.

Separately, it had been reported that some other CRSP insiders also took part of the insider trading activity. CEO, Kulkarni Samarth had divested 15,000 shares for $147,819 through a trade on 2018/06/01. Following this activity, the insider holds 1,040,400 shares worth $5,461,912 as of recent close.Wall Street’s most bullish CRISPR Therapeutics AG (NASDAQ:CRSP) analysts are predicting the share price to blow past $86 per share during the next 12 months. The current median share price forecast by them is $65, suggesting that the stock could increase 75.91% in that time frame. The average price target of $67.5 calls for a nearly 82.68% increase in the stock price.

CRISPR Therapeutics AG (CRSP) trading activity significantly improved as the volume at ready counter increased to 3,002,383 shares versus 1,367,085 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 1,238,548 shares. The share price rose 0.85% in recent trade and currently has a stock-market value of $1.85B. The shares finished at $36.95, after trading as low as $36.65 earlier in the session. It hit an intraday high Thursday at $41.5. The stock is now 123.8% above against its bear-market low of $16.51 on November 09, 2017. It has retreated -100% since it’s 52-week high of $73.9 reached in May. Now the market price is up 96.54% on the year and up 57.37% YTD.

CRSP’s 50 day simple moving average (SMA 50) price is $47.6 and its 200-day simple moving average (SMA 200) price is $49.36. The company’s stock currently has a total float of 32.22M shares. Its weekly volatility is hovering around 7.94% and felt 6.3% volatility in price over a month. On the upside, the share price will test short term resistance at around $40.08. On a downside, the stock is likely to find some support, which begins at $35.23. The failure to get near-term support could push it to $33.52.

It had seen a new analyst call from Wells Fargo, which initiated the stock at Outperform on October 10. Analysts at Guggenheim, started covering the stock on October 10 with a Neutral rating. Analysts at Raymond James, made their first call about the stock on September 21, recommending it is Underperform. Chardan Capital Markets, reiterated their call for Buy, on May 15. On the other hand, they had set new target price to $72.50 versus $25.

The insider holding in CRISPR Therapeutics AG (CRSP) stood at 2.8% while institutions hold 37.3%. Versant Venture Management, Llc is the largest single holder among mutual funds with ownership of over 3.61M CRSP shares as of June 30, with a market value of approx. $212.06M as of today. The second largest holder, Nea Management Company, Llc, with 2.09M shares which equates to $122.85M worth of the stock. At third is Abingworth Llp, which stood pat with 1.24M shares, a 3.93% position in CRISPR Therapeutics AG, worth $72.7M.

Also, it is trading at rather expensive levels at just over 6.53x price/book and 49.73x price/sales. CRSP’s ROE is -39.6%, which is also considerably worse than the industry’s ROE of 1.12%. It’s also very liquid in the near term, with a current ratio of 17.9. The stock has a debt/capital of 0.

Shares of CRISPR Therapeutics AG (CRSP) have dropped -24.7% since the company’s Dec-18 earnings report. Over the past 7 fiscal quarters, CRISPR Therapeutics AG (NASDAQ:CRSP) has topped consensus earnings estimates in 3 quarters (37%), missed earnings in 4 quarters (50%), whereas at 0 occasion EPS met analyst expectations. CRSP last reported earnings on August 07, 2018 when it released Jun-18 results that receded expectations. The company raked in -$0.82 per share, -97.27% change on the same period last year. That was worse than consensus for -$0.63. Revenue for the recent quarter stood at $1.09 million, down -70% on last year and below the $1.83 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $500000 to $11.3 million, which should be compared with $7.8 million generated last year. EPS is seen in a range of -$0.92 to -$0.61, against the -$1.06 reported a year ago.